We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
On Dec 15, we issued an updated research report on Zimmer Biomet Holdings, Inc. (ZBH - Free Report) . The company continues to gain market share in the Asia Pacific (APAC), Europe, the Middle East and Africa (EMEA) regions. However, pricing continues to be a major concern. The stock currently has a Zacks Rank #3 (Hold).
Over the past year, Zimmer Biomet has underperformed its industry. The stock has lost 5.6% against 0.4% rise of the industry. Zimmer Biomet ended the third quarter of 2020 with a slower return in regions within EMEA. The pace of procedure volume and patient returns slowed toward the end of the quarter.
In terms of operating segments, the global knee business declined 47% while the global hip business declined 1.4% in the third quarter. The business registered dull growth outside the United States. Overall business in the EMEA decreased 5.7% and the company observed a slowing recovery rate in September due to the recent COVID-19 surges and corresponding policy actions. In APAC, India and other small Southeast Asian countries continued to significantly underperform the broader region.
According to Zimmer Biomet, the impact of COVID-19 is still significant and remains fluid. Owing to lack of clarity around the scope and duration of the pandemic, the company is still unable to gauge the impact on its overall business in 2020. Accordingly, it has not provided any full-year guidance.
On a positive note, Zimmer Biomet noted that the quarter had clearly shown signs of recovery. According to the company, the overall performance was better than expected across all regions in the third quarter. In particular, it saw a steeper rate of recovery in July, followed by a more modest recovery or even a flattening of the curve toward the end of the quarter. According to Zimmer Biomet, the company returned to growth over 2019 faster than it had expected.
Stronger recovery was seen in the Americas and Asia Pacific while there was a slower return in regions within Europe, the Middle East and Africa (EMEA).
The company is also performing well in its priority areas like quality remediation, supply recovery efforts and product introductions. With respect to quality remediation, it made a good progress in the third quarter.
Of late, Zimmer Biomet has been solidifying its foothold in the emerging markets offering long-term opportunities. The company’s strategic investments in these zones over the last several quarters to improve its operational and sales performance are yielding results. It expects consistent growth in the APAC and EMEA markets this year.
The company should benefit from favorable long-term trends, driven by obesity, wear and tear of joints from more active lifestyles, uptick in the emerging markets, new material technologies, advancements in the surgical techniques and proven clinical benefits of joint replacement procedures.
Key Picks
Some better-ranked stocks from the broader medical space include Hologic (HOLX - Free Report) , Thermo Fisher Scientific (TMO - Free Report) and ResMed (RMD - Free Report) .
Thermo Fisher’s long-term earnings growth rate is estimated at 18%. It currently carries a Zacks Rank #2 (Buy).
ResMed’s long-term earnings growth rate is estimated at 14.5%. The company presently carries a Zacks Rank #2.
Zacks Names “Single Best Pick to Double”
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
You know this company from its past glory days, but few would expect that it’s poised for a monster turnaround. Fresh from a successful repositioning and flush with A-list celeb endorsements, it could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in a little more than 9 months and Nvidia which boomed +175.9% in one year.
Image: Bigstock
Zimmer Biomet (ZBH) Shows Strong Recovery Amid COVID-19 Woes
On Dec 15, we issued an updated research report on Zimmer Biomet Holdings, Inc. (ZBH - Free Report) . The company continues to gain market share in the Asia Pacific (APAC), Europe, the Middle East and Africa (EMEA) regions. However, pricing continues to be a major concern. The stock currently has a Zacks Rank #3 (Hold).
Over the past year, Zimmer Biomet has underperformed its industry. The stock has lost 5.6% against 0.4% rise of the industry. Zimmer Biomet ended the third quarter of 2020 with a slower return in regions within EMEA. The pace of procedure volume and patient returns slowed toward the end of the quarter.
In terms of operating segments, the global knee business declined 47% while the global hip business declined 1.4% in the third quarter. The business registered dull growth outside the United States. Overall business in the EMEA decreased 5.7% and the company observed a slowing recovery rate in September due to the recent COVID-19 surges and corresponding policy actions. In APAC, India and other small Southeast Asian countries continued to significantly underperform the broader region.
Zimmer Biomet Holdings, Inc. Price
Zimmer Biomet Holdings, Inc. price | Zimmer Biomet Holdings, Inc. Quote
According to Zimmer Biomet, the impact of COVID-19 is still significant and remains fluid. Owing to lack of clarity around the scope and duration of the pandemic, the company is still unable to gauge the impact on its overall business in 2020. Accordingly, it has not provided any full-year guidance.
On a positive note, Zimmer Biomet noted that the quarter had clearly shown signs of recovery. According to the company, the overall performance was better than expected across all regions in the third quarter. In particular, it saw a steeper rate of recovery in July, followed by a more modest recovery or even a flattening of the curve toward the end of the quarter. According to Zimmer Biomet, the company returned to growth over 2019 faster than it had expected.
Stronger recovery was seen in the Americas and Asia Pacific while there was a slower return in regions within Europe, the Middle East and Africa (EMEA).
The company is also performing well in its priority areas like quality remediation, supply recovery efforts and product introductions. With respect to quality remediation, it made a good progress in the third quarter.
Of late, Zimmer Biomet has been solidifying its foothold in the emerging markets offering long-term opportunities. The company’s strategic investments in these zones over the last several quarters to improve its operational and sales performance are yielding results. It expects consistent growth in the APAC and EMEA markets this year.
The company should benefit from favorable long-term trends, driven by obesity, wear and tear of joints from more active lifestyles, uptick in the emerging markets, new material technologies, advancements in the surgical techniques and proven clinical benefits of joint replacement procedures.
Key Picks
Some better-ranked stocks from the broader medical space include Hologic (HOLX - Free Report) , Thermo Fisher Scientific (TMO - Free Report) and ResMed (RMD - Free Report) .
Hologic’s long-term earnings growth rate is estimated at 17.4%. The company presently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Thermo Fisher’s long-term earnings growth rate is estimated at 18%. It currently carries a Zacks Rank #2 (Buy).
ResMed’s long-term earnings growth rate is estimated at 14.5%. The company presently carries a Zacks Rank #2.
Zacks Names “Single Best Pick to Double”
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
You know this company from its past glory days, but few would expect that it’s poised for a monster turnaround. Fresh from a successful repositioning and flush with A-list celeb endorsements, it could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in a little more than 9 months and Nvidia which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>